Lumacaftor (VX-809), tezacaftor, and FDL169 were identified as correctors targeting CF, where they bind to defective F508del-CFTR protein to normalize mutant folding functionally, although without direct structural correction evidence (17–19). The gene discussed is CFTR; the disease is cystic fibrosis.